Key result
Racecadotril treats acute diarrhea by inhibiting pathologic intestinal secretion without altering GI transit or motility.
Why the study?
Racecadotril has been tested in animal models and patients across analgesia, cardiovascular diseases, and acute diarrhea, but its clinical effects and therapeutic benefits remain to be comprehensively reviewed.
Does racecadotril provide therapeutic benefit in analgesia, cardiovascular diseases, or acute diarrhea compared to existing treatments?
Population
Animal models and patients in analgesia, cardiovascular diseases, and acute diarrhea including adults and children
Comparison
Racecadotril versus existing cardiovascular treatments and loperamide for acute diarrhea
Design
Comprehensive review
Authors
Loading...
Racecadotril boosts ANP via NEP inhibition; leaves open any cardiovascular role pending randomized trials.
Does racecadotril provide therapeutic benefit in analgesia, cardiovascular diseases, or acute diarrhea compared to existing treatments?
While racecadotril is an effective and well-tolerated treatment for acute diarrhea, it does not offer substantial clinical benefits for cardiovascular diseases such as heart failure or hypertension.
Eberlin et al. (2012) conducted a review in Acute diarrhea, cardiovascular diseases, and pain. Racecadotril vs. Placebo or active comparators (e.g., loperamide) was evaluated. Racecadotril is consistently effective in treating various forms of acute diarrhea by inhibiting pathologic intestinal secretion without altering gastrointestinal transit time or motility.
Synapse has enriched one closely related paper. Consider it for comparative context: